<DOC>
	<DOCNO>NCT01497821</DOCNO>
	<brief_summary>This first-in-human ( Phase I ) study AMG 172 , antibody drug conjugate ( ADC ) , subject kidney cancer [ Clear Cell Renal Cell Carcinoma ( ccRCC ) ] relapse refractory disease follow least two prior therapy . The purpose study evaluate safety pharmacokinetics ( PK ) AMG 172 , also evaluate objective response rate patient ccRCC receive AMG 172 . The study conduct two Parts : Part 1 explore dos AMG 172 give every two week every three week determine safety , tolerability pharmacokinetics establish maximum tolerate dose ( MTD ) , Part 2 ( dose expansion ) examine safety , tolerability , PK overall response rate subject treat MTD establish Part 1 either every two week every three week dosing .</brief_summary>
	<brief_title>AMG 172 First Human Study Patients With Kidney Cancer</brief_title>
	<detailed_description>This First in- human study AMG 172 conduct two part : Part 1 ( dose exploration ) Part 2 ( dose expansion ) . Part 1 study aim evaluate safety , tolerability PK AMG 172 give every two week every three week subject relapsed / refractory cc RCC , Part 2 aim evaluate safety , tolerability , PK response rate subject treat MTD establish Part 1 either every two week every three week dose . Up 48 subject may enrol Part 1 , 30 subject may enrol Part 2 . The dose AMG 172 utilized Part 2 dependent upon data obtain Part 1 study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<criteria>Subjects must pathologically document , definitively diagnose , clear cell RCC relapsed/refractory follow least two line systemic therapy ( one must tyrosine kinase ) , subject refuse standard therapy Measurable disease per RECIST 1.1 criterion . Subjects nonmeasurable , evaluable disease also eligible Part 1 study . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 1 Willing provide tumor sample / slide Hematological function , follow : 1 . Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L ; 2 . Platelet count ≥ 100 x 10^9/L ; 3 . Hemoglobin &gt; 9 g/dL Prothrombin time ( PT ) partial thromboplastin time ( PTT ) &lt; 1.5 x institutional upper limit normal ( IULN ) Hepatic function , follow : 1 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 3 x ULN ; 2 . Total bilirubin &lt; 1.5 x ULN ( &lt; 3.0 x ULN subject document Gilbert 's Disease indirect bilirubin level suggest extrahepatic source elevation ) ; 3 . Alkaline phosphatase &lt; 2 x ULN ( &lt; 5 x ULN subject PI sponsor agree clinical data suggest extrahepatic source elevation ) Other inclusion criterion may apply Known primary central nervous system ( CNS ) tumor brain metastasis History bleed diathesis Myocardial infarction within 6 month study day 1 , symptomatic congestive heart failure ( New York Heart Association &gt; class II ) , unstable angina , unstable cardiac arrhythmia require medication , uncontrolled hypertension opinion investigator Clinically significant ECG change obscure ability ass PR , QT , QRS interval ; congenital long QT syndrome A baseline ECG QTcF &gt; 470 msec Known positive test human immunodeficiency virus ( HIV ) Known acute chronic hepatitis B hepatitis C infection determine serologic test Other exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Amgen</keyword>
	<keyword>Phase 1</keyword>
	<keyword>First Human</keyword>
	<keyword>Relapsed / Refractory Renal Cell Carcinoma ( RCC )</keyword>
	<keyword>Kidney Cancer</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Antibody drug conjugate ( ADC )</keyword>
	<keyword>Open-label</keyword>
	<keyword>Oncology</keyword>
</DOC>